Lesaffre has acquired Italian biotechnology company Gnosis, which specialises in the development, production and sale of fermentation-derived ingredients for the food and nutraceutical industries.
Lesaffre has held a majority stake in Gnosis since 2015, and has now fully-acquired the company for an undisclosed fee, enhancing its presence in the nutritional ingredients sector.
Gnosis will be integrated into the Lesaffre Human Care unit, allowing Lesaffre to produce a unified range of products and services to its nutritional ingredients and human health customers and partners.
The company will acquire Gnosis’ GMP manufacturing sites in Sant Antonino, Switzerland and Pisticci, Italy as part of the transaction, as well as Gnosis’ commercial offices and its R&D facility.
Antoine Baule, Lesaffre’s CEO: “For the past three years, we have developed the cooperation between Lesaffre and Gnosis teams to become today a unique provider of products and services that are increasingly innovative and closely address our customer’s needs in the nutrition and health sectors.
“I would like to thank Renzo Berna, former CEO of Gnosis, for his relentless dedication to building a successful company, and my respect for the great accomplishment of his purpose.”
Renzo Berna, former CEO of Gnosis added: “Developing Gnosis has been an exciting challenge.
“After 25 years, Gnosis has become a reference on the market able to design and manufacture fermentation purified metabolites as health care active ingredients for the nutraceutical and pharmaceutical markets.
“I am convinced that Lesaffre, a family group known and recognised internationally for its professionalism and the quality of its products and services will take this company even further forwards.
“I wish Marc Philouze, the general manager of this new entity a lot of success for the promising future.”
© FoodBev Media Ltd 2024
